Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B

Clinical Infectious Diseases

Volumn 53, Issue 11, 2011, Pages 1143-1152

  Scherrer, Alexandra U ^a   Ledergerber, Bruno ^a   Von Wyl, Viktor ^m   Böni, Jürg ^b   Yerly, Sabine ^d   Klimkait, Thomas ^f   Bürgisser, Philippe ^h   Rauch, Andri ^j   Hirschel, Bernard ^e   Cavassini, Matthias ⁱ   Elzi, Luigia ^g   Vernazza, Pietro L ^k   Bernasconi, Enos ^l   Held, Leonhard ^c   Günthard, Huldrych F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Swiss National Center for Retroviruses   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d Laboratory of Virology   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h Division of Immunology and Allergy   (Switzerland)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j UNIVERSITY OF BERN   (Switzerland)

^k CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^l REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS TYPING;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; SWITZERLAND; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80755129262     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir669     Document Type: Article

References (30)

1. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-23. (Pubitemid 44611051)
2. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007;6:1001-18. (Pubitemid 350213865)
3. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-8. (Pubitemid 29126872)
4. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005;366:378-84. (Pubitemid 41073955)
5. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000;38:3919-25. (Pubitemid 32233182)
6. Martinez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev 2008;10:212-23.
7. Taylor BS, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008;359:1965-6.
8. Alexander CS, Montessori V, Wynhoven B, et al. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther 2002;7:31-5. (Pubitemid 36285549)
9. Bannister WP, Ruiz L, Loveday C, et al. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther 2006;11:707-15. (Pubitemid 44497166)
10. Bocket L, Cheret A, Deuffic-Burban S, et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 2005;10:247-54. (Pubitemid 41151031)
11. Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005;38:545-52. (Pubitemid 40524476)
12. Easterbrook PJ, Smith M, Mullen J, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 2010;13:4.
13. Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002;16:1139-46. (Pubitemid 34533852)
14. Geretti AM, Harrison L, Green H, et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009;48:1296-305.
15. Pillay D, Walker AS, Gibb DM, et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002;186:617-25. (Pubitemid 34925533)
16. Hartzell JD, Spooner K, Howard R, Wegner S, Wortmann G. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr 2007;44:411-6. (Pubitemid 46555375)
17. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr 2007;46:547-54. (Pubitemid 350191047)
18. Atlas A, Granath F, Lindstrom A, Lidman K, Lindback S, Alaeus A. Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy. AIDS Res Hum Retroviruses 2005;21:221-7. (Pubitemid 40478230)
19. Ribaudo H, Smith H, Robbins G, et al. Race differences in the efficacy of initial ART on HIV infection in randomized trials undertaken by ACTG [abstract 50]. In: Program &Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: CROI, 2011.
20. Muller V, von Wyl V, Yerly S, et al. African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. AIDS 2009;23:1269-76.
21. Rauch A, Nolan D, Furrer H, et al. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin Infect Dis 2008;46:1921-5.
22. Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 2010;39:1179-89.
23. Von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007;167:1782-90. (Pubitemid 47403067)
24. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21:3797-800. (Pubitemid 41535530)
25. Glass TR, De Geest S, Hirschel B, et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther 2008;13:77-85. (Pubitemid 351541676)
26. Yerly S, von Wyl V, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007;21:2223-9. (Pubitemid 350287221)
27. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-2. (Pubitemid 34270738)
28. Fox J, Castro H, Kaye S, McClure M, Weber JN, Fidler S. Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS 2010;24:2397-401.
29. Abecasis AB, Deforche K, Bacheler LT, et al. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02 AG. Antivir Ther 2006;11:581-9. (Pubitemid 44277423)
30. Lawrence P, Lutz MF, Saoudin H, et al. Analysis of polymorphism in the protease and reverse transcriptase genes of HIV type 1 CRF02-AG subtypes from drug-naive patients from Saint-Etienne, France. J Acquir Immune Defic Syndr 2006;42:396-404. (Pubitemid 44050885)